Benign serous ovarian tumour: a redefining moment?

by Hunter Sally, Gorringe Kylie, Anglesio Michael, Sharma Raghwa, Gilks Blake, deFazio Anna, Huntsman David, Campbell Ian
Published 2012-04-01

High resolution melting for mutation scanning of <it>TP53 </it>exons 5–8

by Fox Stephen B, deFazio Anna, Hyland Sarah J, Etemadmoghadam Dariush, Ahmed Ahmed, Krypuy Michael, Brenton James D, Bowtell David D, Dobrovic Alexander
Published 2007-08-01

Helplessness/hopelessness, minimization and optimism predict survival in women with invasive ovarian cancer: a role for targeted support during initial treatment decision-making?

by Price, Melanie A, Butow, Phyllis N, Bell, Melanie L, deFazio, Anna, Friedlander, Michael, Fardell, Joanna E, Protani, Melinda M, Webb, Penelope M
Published 2016

MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome

by Fanayan Susan, Scurry James P, Murali Rajmohan, Gloss Brian S, Hardy Jayne R, Maleki Sanaz, Byrne Jennifer A, Emmanuel Catherine, Hacker Neville F, Sutherland Robert L, deFazio Anna, O'Brien Philippa M
Published 2010-09-01

Identification of a genetic variant associated with treatment outcome in ovarian cancer: the potential role of cholesterol metabolism as a determinant of response to chemotherapy

by Chenevix-Trench Georgia, Lu Yi, Johnatty Sharon, Gamazon Eric, Beesley Jonathan, Chen Xiaoqing, Gao Bo, Harnett Paul, Stephanie Huang R, Despierre Evelyn, Heitz Florian, Hogdall Estrid, Hogdall Claus, Brown Robert, Moyisch Kirsten, Fasching Peter, Goode Ellen, Russell Amanda, Henderson Michelle, Haber Michelle, Dolan Eileen, Macgregor Stuart, deFazio Anna
Published 2012-04-01